Ras
Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.
Ras Isoform Specific Products
All Product Categories
-
Ras Related Products (723)
Related Products (723)
-
Antibodies (36)
-
Ras Isoform Comparison
-
Pan-RAS-IN-7
0 ImagesCat. No.: HY-164802CAS No.: 2642135-72-4
-
KRas G12C inhibitor 3
0 ImagesCat. No.: HY-112493CAS No.: 2206735-75-1KRas G12C inhibitor 3 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
-
SOS1-IN-18
0 ImagesCat. No.: HY-172221SOS1-IN-18 (Compound 8) is the inhibitor for Son of Sevenless 1 protein (SOS1) with a KD of 2.6 nM, and inhibits SOS1-KRAS G12C interaction with an IC50 of 3.4 nM. SOS1-IN-18 inhibits the phosphorylation of ERK in H358 with an IC50 of 31 nM, inhibits the proliferation of H358 with an IC50 of 5 nM.
-
PROTAC K-Ras Degrader-6
0 ImagesCat. No.: HY-168678CAS No.: 3052745-46-4PROTAC K-Ras Degrader-6 (compound 102) is a potent cereblon-based KRAS PROTAC degrader, with a DC50 of ≤100 nM. PROTAC K-Ras Degrader-6 shows anticancer effects.
-
SOS1-IN-5
0 ImagesCat. No.: HY-145048CAS No.: 2716956-47-5SOS1-IN-5 is a potent inhibitor of SOS1. SOS1-IN-5 is a pyrimidobicyclic derivative. SOS1-IN-5 blocks the activation of KRAS by interfering with RAS-SOS1 interaction, and achieves the purpose of broad-spectrum inhibition of KRAS activity. SOS1-IN-5 has the potential for the research of cancer diseases (extracted from patent WO2021203768A1, compound 4).
-
KARS-IN-1
0 ImagesCat. No.: HY-180562CAS No.: 2579083-99-9KARS-IN-1 (152) is a AKR1C3 dependent KARS inhibitor with an AC50 of 9.1 nM for human KARS. KARS-IN-1 shows anti-proliferative activity in H460 (NRF2 pathway mutant cell line with high AKR1C3 expression) and Hara (NRF2 pathway wild type cell line with low AKR1C3 expression), with AC50 values ??of 21 nM and 16 nM, respectively. KARS-IN-1 can be used for the study of non-small cell lung cancer (NSCLC).
-
CE3F4 analog 1
0 ImagesCE3F4 analog 1 is an analogue of CE3F4.
-
Erufosine
0 ImagesCat. No.: HY-171777CAS No.: 202867-33-2Synonyms: ErPC3; ErucylphosphohomocholineErufosine is an inhibitor of PI3K/Akt and Ras/Raf/MAPK signaling pathways. Erufosine inhibits the activity of breast cancer cell lines MCF-7 and MDA-MB 231 (IC50: 40.95/40.8 μM). Erufosine reduces the phosphorylation of PI3K (p85), Akt (PKB), and cRaf. Erufosine can be used in the study of breast cancer and myeloid leukemia.
-
pan-KRAS-IN-4
0 ImagesCat. No.: HY-156528CAS No.: 2885961-55-5pan-KRAS-IN-4 (compound 5) is a potent inhibitor of KRAS with IC50s of 0.37 nM (Kras G12C), 0.19 nM (Kras G12V), respectively.
-
KRAS G12C inhibitor 34
0 ImagesCat. No.: HY-142511CAS No.: 2749948-26-1KRAS G12C inhibitor 34 is a KRAS G12C inhibitor extracted from patent WO2021239058A1, compound Z1. KRAS G12C inhibitor 34 can be used for the research of cancer.
-
KRAS G12C inhibitor 68
0 ImagesCat. No.: HY-159611CAS No.: 3034851-27-6KRAS G12C inhibitor 68 (compound I-063) is a KRAS G12C inhibitor with an IC50 of 7 nM. KRAS G12C inhibitor 68 has anti-tumor activity.
-
K20
0 ImagesCat. No.: HY-115907K20 is a potent and selective KRas G12C inhibitor with an IC50 of 1.16 µM. K20 shows anticancer activity in H358 cells (IC50= 0.78 µM). K20 decreases the levels of phosphorylated Erk and leads to cancer cell apoptosis. K20 suppresses NCI-H358 tumor growth with a TGI of 41% without causing obvious toxicity.
-
(R)-ACBI-4
0 ImagesCat. No.: HY-176792ACAS No.: 3097973-97-9
-
KRAS G12D inhibitor 7
0 ImagesCat. No.: HY-139911CAS No.: 2648552-34-3KRAS G12D inhibitor 7 is an inhibitor of KRAS G12D. KRAS G12D inhibitor 7 can be used for the research of cancer.
-
KRAS G12C inhibitor 42
0 ImagesCat. No.: HY-143598CAS No.: 2454488-02-7KRAS G12C inhibitor 42 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 42 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2020146613A1, compound 10).
-
GIT1-IN-1
0 ImagesCat. No.: HY-181978CAS No.: 844464-54-6GIT1-IN-1 is an inhibitor of ARF GTPase-activating protein 1 (GIT1) with a KD of 6.2 μM. GIT1-IN-1 induces apoptosis (apoptosis) in liver and colon cancer cells, arrests the cell cycle at the G2/M phase, and inhibits cell proliferation, colony formation and migration. GIT1-IN-1 inhibits the activities of MEK and ERK, reduces the expression level of cyclin D1, and stabilizes cyclin B1 protein in liver and colon cancer cells. GIT1-IN-1 can be used in the research of liver cancer and colon cancer.
